Efficacy and Safety of Kabalin Cap.(Pregabalin) in Patients With Neuropathic Pain
A Multi-center, Prospective, Observational Study to Evaluate Therapeutic Effectiveness and Safety of Kabalin Cap. in Patients With Neuropathic Pain
This study aims to assess the proportion of patients with peripheral or central neuropathic pain who achieve at least a 50% improvement in pain at Week 12 after receiving Kabalin Cap.(Pregabalin). The study will also evaluate changes in pain characteristics, severity, and intensity; improvement in pain-related sleep interference; and safety information collected during the study period.
研究概览
地位
详细说明
This study will evaluate pain-related outcomes and safety in patients with peripheral or central neuropathic pain who receive Kabalin Cap.(Pregabalin). At Week 12 after treatment initiation, the proportion of patients who achieve at least a 50% improvement in pain will be assessed. Changes in pain characteristics, severity, and intensity will also be evaluated. In addition, the study will assess improvement in pain-related sleep interference and collect safety information observed during the study period.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Yong-an Jeong
- 电话号码:+82-31-5176-4673
- 邮箱:yongan.jeong@inno-n.com
研究联系人备份
- 姓名:Seung kye Cho
- 电话号码:+82-31-5176-4676
- 邮箱:seungkye.cho@inno-n.com
学习地点
-
-
-
Seoul、韩国
- 招聘中
- HK inno.N
-
接触:
- Seung Kye Cho
- 电话号码:+82-31-5176-4676
- 邮箱:seungkye.cho@inno-n.com
-
接触:
- Ahrong Kim
- 电话号码:+82-31-5176-4666
- 邮箱:ahrong.kim@inno-n.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
University-affiliated hospitals and general hospitals where the study drug is administered
描述
Inclusion Criteria:
- Aged 19 years or older
- Patients for whom treatment with Kabalin Cap. has been selected in accordance with the approved prescribing information for peripheral or central neuropathic pain
- Patients who voluntarily provide written informed consent
- Patients who are able to complete the questionnaires
Exclusion Criteria:
- Patients with hypersensitivity to pregabalin or any of the excipients
- Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- Pregnant or breastfeeding women
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with a ≥50% improvement in pain severity from baseline at Week 12
大体时间:At Week 12 after enrollment
|
The proportion of participants whose pain severity score, as assessed using the SF-MPQ, shows a ≥50% improvement from baseline after 12 weeks of treatment with Kabalin Cap. will be reported |
At Week 12 after enrollment
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.